Tele: 561.316.3330
Breaking Medical Device News

Monday, September 27, 2021
HomeNON PROFITAppropriate Use Criteria (AUC) for the Management of Rotator Cuff Pathology Fact Sheet

Appropriate Use Criteria (AUC) for the Management of Rotator Cuff Pathology Fact Sheet

September 22, 2020

The American Academy of Orthopaedic Surgeons (AAOS) released an AUC to report on the optimal management of symptomatic full-thickness rotator cuff tears based on expert experience and review of the literature as an appropriate use document. The treatment scenarios provided by this AUC stem from the recommendations in the Clinical Practice Guideline (CPG) issued by the AAOS in March 2019.


This AUC is intended to offer guidance on decision factors for adults with rotator cuff tears. The AUC online tool provides clinicians algorithms on how to optimally evaluate the condition based on a patient’s various indications, including injury or degeneration. It recommends specific next steps and procedures to ensure optimal recovery. The target patient group is assumed to have a:

  • Clinical history such as anterolateral shoulder pain not radiating past the elbow;
  • Physical examination such as weakness with testing rotator cuff strength, positive lift off or belly press test, external rotation lag, positive drop arm test, and/or pain relief but sustained weakness after impingement test;
  • Imaging findings (MRI or ultrasound) all consistent with a full-thickness rotator cuff tear.

For surgical candidates with any other concomitant diagnoses, such as biceps tendonitis, labral fraying/tearing, and acromioclavicular arthritis with osteophytes, these AUC may still be applicable if the candidate meets both of the following conditions:

  1. After the history, exam, and imaging review, the clinician determines that the rotator cuff tear accounts for the majority of the symptoms.
  2. Treatment of this secondary pathology is necessary as part of the surgical procedure to treat potential pain generators and relieve pathology that may deteriorate the surgical outcome.

The conditions listed below are specifically not addressed in these AUC:

  • Rotator cuff re-tears/history of previous rotator cuff repair
  • Partial-thickness tears or rotator cuff tendonitis/ rotator cuff bursitis
  • Secondary diagnosis that the surgeon determines is more likely to be the relevant pathology creating pain such as: Glenohumeral Arthrosis, calcific tendinitis, plexopathy, radiculopathy or muscle weakness from SSN nerve compression, isolated clinically symptomatic AC joint arthritis

The new AUC is geared towards the needs of sports medicine and shoulder and elbow orthopaedic surgeons; however, healthcare professionals other than orthopaedic surgeons, including but not limited to adult primary care physicians, adult medicine specialists, physical therapists, occupational therapists, physician assistants, nurse practitioners who routinely see this patient population in various practice settings may benefit from this tool. This AUC tool is not intended for use as a benefits determination document.

The AUC tool offers accepted approaches to treatment and/or diagnosis and is not intended to be a fixed protocol. Patient care and treatment should always be based on a clinician’s independent medical judgment, giving the individual patient’s specific clinical circumstances.

The full AUC for the evaluation of psychosocial factors influencing recovery from adult orthopaedic trauma is available through AAOS’ OrthoGuidelines website and free mobile app. For more information on the development process for AAOS clinical practice guidelines, please reference the Clinical Practice Guideline Methodology.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

ProSomnus® Sleep Technologies Adds John E. Remmers, MD, to Leadership Team

Dr. John E. Remmers will provide expert medical and strategic guidance on a range of initiatives, including research and development, regulatory clearances, company strategy, medical education, and clinical investigations.

Nanox to Announce Zebra Medical Vision Secures 8th 510K FDA Clearance for its Coronary Artery Calcium (CAC) Solution as Part of Its Population Health Offering

On August 10th, 2021 Nanox announced that it had entered into an acquisition agreement via merger with Zebra Medical Vision LTD.

Christopher Joyce Joins Miach Orthopaedics as VP & CFO

Christopher Joyce has joined as vice president and chief financial officer, and Kevin Sidow has been appointed to the company’s board of directors.

NGMedical GmbH Receives FDA Clearance for Its AM Titanium Lumbar Interbody BEE® PLIF

The BEE® PLIF cage has been created to benefit from additive manufacturing features. The purposefully designed honeycomb endplate design reduces the risk of subsidence, while allowing fusion.

Recombinant Technologies is Raising Capital to Roll Out a Game Changing Alzheimer’s Treatment

Recombinant Technologies is focused on treating the root cause of Alzheimer's Disease delivering a huge improvement in the quality of life of those afflicted.

Tyber Medical Reaches Agreement to Acquire CatapultMD

Once the acquisition is complete, Tyber Medical will own and operate a combined 100,000-square feet of manufacturing space between its Pennsylvania headquarters and Florida-based facilities.

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

By using this website you agree to accept Medical Device News Magazine Privacy Policy